Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...

EXCLUSIVE: Traitors star Leanne Quigley has opened up about the heartbreaking breast cancer battle her fiancee Sophie Jones ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

The Traitors winner Leanne Quigley opens up movingly on the most traumatic two years of her life - as she admits her and ...

OS Therapies (OSTX) announced that it received a notice of allowance from the United States Patent & Trademark Office that a patent will be ...